<!DOCTYPE html>
<html lang="en">

<head>
  <meta http-equiv="content-type" content="text/html; charset=utf-8">
<meta name="x5-fullscreen" content="true">
<meta name="full-screen" content="yes">
<meta name="theme-color" content="#317EFB" />
<meta content="width=device-width, initial-scale=1.0, maximum-scale=5.0, user-scalable=0" name="viewport">
<meta name="description" content="TIP这些是本篇文章的标签，来发现更多感兴趣的内容吧医学考研复试肺结节胸外科临床思维靶向治疗化疗免疫治疗   来源：BV1wv4y1J7je    1.肺癌的药物治疗原则与常用方案  NSCLC的分类，分期，分型和治疗概述 肺癌是起源于支气管黏膜，腺体或肺泡上皮的肺部恶性肿瘤 肺癌的组织学分类：NSCLC约占所有肺癌的85% WHO基于肺癌的生物学特征、治疗和预后，将肺癌主要分为非小细胞肺癌NSC">
<meta property="og:type" content="article">
<meta property="og:title" content="肺癌的药物治疗原则与常用方案">
<meta property="og:url" content="http://example.com/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E8%82%BA%E7%99%8C%E7%9A%84%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97%E5%8E%9F%E5%88%99%E4%B8%8E%E5%B8%B8%E7%94%A8%E6%96%B9%E6%A1%88/index.html">
<meta property="og:site_name" content="Flynn&#39;s Blog">
<meta property="og:description" content="TIP这些是本篇文章的标签，来发现更多感兴趣的内容吧医学考研复试肺结节胸外科临床思维靶向治疗化疗免疫治疗   来源：BV1wv4y1J7je    1.肺癌的药物治疗原则与常用方案  NSCLC的分类，分期，分型和治疗概述 肺癌是起源于支气管黏膜，腺体或肺泡上皮的肺部恶性肿瘤 肺癌的组织学分类：NSCLC约占所有肺癌的85% WHO基于肺癌的生物学特征、治疗和预后，将肺癌主要分为非小细胞肺癌NSC">
<meta property="og:locale" content="en_US">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="og:image" content="http://example.com/img/404.jpg">
<meta property="article:published_time" content="2024-10-24T05:07:26.530Z">
<meta property="article:modified_time" content="2024-10-24T05:07:26.530Z">
<meta property="article:author" content="Flynn">
<meta property="article:tag" content="靶向治疗">
<meta property="article:tag" content="医学">
<meta property="article:tag" content="考研复试">
<meta property="article:tag" content="肺结节">
<meta property="article:tag" content="胸外科">
<meta property="article:tag" content="临床思维">
<meta property="article:tag" content="化疗">
<meta property="article:tag" content="免疫治疗">
<meta name="twitter:card" content="summary">
<meta name="twitter:image" content="http://example.com/img/404.jpg">


<title >肺癌的药物治疗原则与常用方案</title>

<!-- Favicon -->

    <link href='/img/16.svg?v=2.1.13' rel='icon' type='image/png' sizes='16x16' ></link>


    <link href='/img/32.svg?v=2.1.13' rel='icon' type='image/png' sizes='32x32' ></link>




<!-- Plugin -->




    
<link rel="stylesheet" href="/css/plugins/bootstrap.row.css">

    
<link rel="stylesheet" href="https://unpkg.com/@fancyapps/ui@4.0/dist/fancybox.css">

    
    




<!-- Icon -->

    
<link rel="stylesheet" href="/css/plugins/font-awesome.min.css">




<!-- Variable -->
<script>window.ASYNC_CONFIG = {"hostname":"example.com","author":"Flynn","root":"/","typed_text":null,"theme_version":"2.1.13","theme":{"switch":true,"default":"auto"},"favicon":{"logo":"img/200.svg","icon16":"img/16.svg","icon32":"img/32.svg","appleTouchIcon":null,"webmanifest":null,"visibilitychange":true,"hidden":"/failure.ico","showText":"(/≧▽≦/)Hey! Good again!","hideText":"(●—●)Oh, crash!","apple_touch_icon":"img/200.svg"},"i18n":{"placeholder":"Searching...","empty":"We didn't find any results for the search: ${query}.","hits":"${hits} results found","hits_time":"${hits} results found in ${time} ms","author":"Post author: ","copyright_link":"Post link: ","copyright_license_title":"Copyright Notice: ","copyright_license_content":"All articles in this blog are licensed under undefined unless otherwise stated.","copy_success":"Copied","copy_failure":"Copy failed","open_read_mode":"Enter reading mode","exit_read_mode":"Exit reading mode","notice_outdate_message":"It has been undefined days since the last update, the content of the article may be outdated.","sticky":"TOP","just":"Just","min":"minutes ago","hour":"hours ago","day":"days ago","month":"months ago"},"swup":false,"plugin":{"flickr_justified_gallery":"https://unpkg.com/flickr-justified-gallery@latest/dist/fjGallery.min.js"},"icons":{"sun":"far fa-sun","moon":"far fa-moon","play":"fas fa-play","email":"far fa-envelope","next":"fas fa-arrow-right","calendar":"far fa-calendar-alt","clock":"far fa-clock","user":"far fa-user","back_top":"fas fa-arrow-up","close":"fas fa-times","search":"fas fa-search","reward":"fas fa-hand-holding-usd","user_tag":"fas fa-user-alt","toc_tag":"fas fa-th-list","read":"fas fa-book-reader","arrows":"fas fa-arrows-alt-h","double_arrows":"fas fa-angle-double-down","copy":"fas fa-copy"},"icontype":"font","highlight":{"plugin":"highlighjs","theme":true,"copy":true,"lang":true,"title":"default","height_limit":false},"toc":{"post_title":false},"live_time":{"start_time":"2024-02-09 17:00","prefix":"The blog has been lovely to run undefined day"},"danmu":{"enable":false,"el":".trm-banner"},"covers":["/img/banner.jpg","/img/avatar.jpg"],"search":{"enable":true,"type":"local","href":"https://www.google.com/search?q=site:","domain":null,"result_placeholder":"testing..","path":"search.xml"}};</script>
<script id="async-page-config">window.PAGE_CONFIG = {"isPost":true,"isHome":false,"postUpdate":"2024-10-24 13:07:26"};</script>

<!-- Theme mode css -->
<link data-swup-theme rel="stylesheet" href="/css/index.css?v=2.1.13" id="trm-switch-style">
<script>
    let defaultMode = ASYNC_CONFIG.theme.default !=='auto' ?  ASYNC_CONFIG.theme.default : (window.matchMedia("(prefers-color-scheme: light)").matches ? 'style-light' : 'style-dark')
    let catchMode = localStorage.getItem('theme-mode') || defaultMode;
    let type = catchMode === 'style-dark' ? 'add' : 'remove';
    document.documentElement.classList[type]('dark')
</script>

<!-- CDN -->


    
    



<!-- Site Analytics -->
 
<meta name="generator" content="Hexo 7.1.1"></head>

<body>

  <!-- app wrapper -->
  <div class="trm-app-frame">

    <!-- page preloader -->
    <div class="trm-preloader">
    <div class="trm-holder">
        <div class="preloader">
            <div></div>
            <div></div>
            <div></div>
            <div></div>
            <div></div>
            <div></div>
            <div></div>
            <div></div>
            <div></div>
            <div></div>
        </div>
    </div>
</div>
    <!-- page preloader end -->

    <!-- change mode preloader -->
    <div class="trm-mode-swich-animation-frame">
    <div class="trm-mode-swich-animation">
        <i class="i-sun"><i class="iconfont far fa-sun"></i></i>
        <div class="trm-horizon"></div>
        <i class="i-moon"><i class="iconfont far fa-moon"></i></i>
    </div>
</div>
    <!-- change mode preloader end -->

      <!-- scroll container -->
      <div id="trm-dynamic-content" class="trm-swup-animation">
        <div id="trm-scroll-container" class="trm-scroll-container" style="opacity: 0">
            <!-- top bar -->
            <header class="trm-top-bar">
	<div class="container">
		<div class="trm-left-side">
			<!-- logo -->
<a href="/" class="trm-logo-frame trm-anima-link">
    
        <img alt="logo" src="/img/200.svg">
    
    
        <div class="trm-logo-text">
            Flynn<span>姜</span>
        </div>
    
</a>
<!-- logo end -->
		</div>
		<div class="trm-right-side">
			<!-- menu -->
<div class="trm-menu">
    <nav>
        <ul>
            
            <li class="menu-item-has-children ">
                <a  href="/" target="">
                    主页
                </a>
                
            </li>
            
            <li class="menu-item-has-children ">
                <a data-no-swup href="/archives/" target="">
                    归档
                </a>
                
            </li>
            
            <li class="menu-item-has-children ">
                <a  href="/categories/" target="">
                    分类
                </a>
                
            </li>
            
            <li class="menu-item-has-children ">
                <a  href="/tags/" target="">
                    标签
                </a>
                
            </li>
            
            <li class="menu-item-has-children ">
                <a  href="/about/" target="">
                    关于我
                </a>
                
            </li>
            
        </ul>
    </nav>
</div>
<!-- menu end -->
			
    <!-- mode switcher place -->
    <div class="trm-mode-switcher-place">
        <div class="trm-mode-switcher">
            <i class="iconfont far fa-sun"></i>
            <input class="tgl tgl-light" id="trm-swich" type="checkbox">
            <label class="trm-swich" for="trm-swich"></label>
            <i class="iconfont far fa-moon"></i>
        </div>
    </div>
    <!-- mode switcher place end -->

			
    
    <div id="trm-search-btn" class="trm-search-btn">
        <i class="iconfont fas fa-search"></i>
    </div>
     

		</div>
		<div class="trm-menu-btn">
			<span></span>
		</div>
	</div>
</header>
            <!-- top bar end -->

            <!-- body -->
            
<div class="trm-content-start">
    <!-- banner -->
    <div class="trm-banner">
    
    <!-- banner cover -->
    <img style="object-position:top;object-fit:cover;" alt="banner" class="trm-banner-cover" src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/cover2.jpg">
    <!-- banner cover end -->
    

    <!-- banner content -->
    <div class="trm-banner-content trm-overlay">
        <div class="container">
            <div class="row">
                
                <div class="col-lg-4"></div>
                
                <div class="col-lg-8">

                    <!-- banner title -->
                    <div class="trm-banner-text ">
                        <div class="trm-label trm-mb-20">
                            
                        </div>
                        <h1 class="trm-mb-30 trm-hsmb-font">
                            肺癌的药物治疗原则与常用方案
                        </h1>

                        
                            <ul class="trm-breadcrumbs trm-label">
                                <li>
                                    <a href="/" class="trm-anima-link">Home</a>
                                </li>
                                <li>
                                    <span>
                                        临床思维
                                    </span>
                                </li>
                            </ul>
                        
                    </div>
                    <!-- banner title end -->

                    <!-- scroll hint -->
                    <span id="scroll-triger" class="trm-scroll-hint-frame">
                        <div class="trm-scroll-hint"></div>
                        <span class="trm-label">Scroll down</span>
                    </span>
                    <!-- scroll hint end -->

                </div>
            </div>
        </div>
    </div>
    <!-- banner content end -->
</div>
    <!-- banner end -->
    <div class="container">
        <div class="row">
            
                <div class="trm-page-sidebar col-lg-4 hidden-sm">
                    <!-- main card -->
                    <div class="trm-main-card-frame trm-sidebar">
    <div class="trm-main-card"> 
        <!-- card header -->
<div class="trm-mc-header">
    <div class="trm-avatar-frame trm-mb-20">
        <img alt="Avatar" class="trm-avatar" src="/img/flynn.jpg">
    </div>
    <h5 class="trm-name trm-mb-15">
        Flynn
    </h5>
    
</div>
<!-- card header end -->
        <!-- sidebar social -->

<!-- sidebar social end -->
        <!-- info -->
<div class="trm-divider trm-mb-40 trm-mt-40"></div>
<ul class="trm-table trm-mb-20">
    
        <li>
            <div class="trm-label">
                地址:
            </div>
            <div class="trm-label trm-label-light">
                广州/深圳
            </div>
        </li>
    
        <li>
            <div class="trm-label">
                年龄:
            </div>
            <div class="trm-label trm-label-light">
                24
            </div>
        </li>
    
</ul>
<!-- info end -->

        
    <div class="trm-divider trm-mb-40 trm-mt-40"></div>
    <!-- action button -->
    <div class="text-center">
        <a href="mailto:240443192@qq.com" class="trm-btn">
            Contact Me
            <i class="iconfont far fa-envelope"></i>
        </a>
    </div>
    <!-- action button end -->

    </div>
</div>
                    <!-- main card end -->
                </div>
            
            <div class="trm-page-content col-lg-8">
                <div id="trm-content" class="trm-content">
                    <div class="trm-post-info row hidden-sm">
    <div class="col-sm-4">
        <div class="trm-card trm-label trm-label-light text-center">
            <i class="iconfont far fa-calendar-alt trm-icon"></i><br>
            10/24
        </div>
    </div>
    <div class="col-sm-4">
        <div class="trm-card trm-label trm-label-light text-center">
            <i class="iconfont far fa-clock trm-icon"></i><br>
            13:07
        </div>
    </div>
    <div class="col-sm-4">
        <div id="post-author" class="trm-card trm-label trm-label-light text-center">
            <i class="iconfont far fa-user trm-icon"></i><br>
            Flynn
        </div>
    </div>
</div>
<div class="trm-card ">
    <article id="article-container" class="trm-publication">
    <div class="trm-note tip"><div class="trm-note-title">TIP</div><p>这些是本篇文章的标签，来发现更多感兴趣的内容吧<br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E5%8C%BB%E5%AD%A6/">医学</a><br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E8%80%83%E7%A0%94%E5%A4%8D%E8%AF%95/">考研复试</a><br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E8%82%BA%E7%BB%93%E8%8A%82/">肺结节</a><br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E8%83%B8%E5%A4%96%E7%A7%91/">胸外科</a><br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/">临床思维</a><br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E9%9D%B6%E5%90%91%E6%B2%BB%E7%96%97/">靶向治疗</a><br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E5%8C%96%E7%96%97/">化疗</a><br><a target="_blank" rel="noopener" href="http://blog.flynn2059.top/tags/%E5%85%8D%E7%96%AB%E6%B2%BB%E7%96%97/">免疫治疗</a></p>
</div>
<blockquote>
<p>来源：<a target="_blank" rel="noopener" href="https://www.bilibili.com/video/BV1wv4y1J7je/">BV1wv4y1J7je</a>    1.肺癌的药物治疗原则与常用方案</p>
</blockquote>
<h1 id="NSCLC的分类，分期，分型和治疗概述"><a href="#NSCLC的分类，分期，分型和治疗概述" class="headerlink" title="NSCLC的分类，分期，分型和治疗概述"></a>NSCLC的分类，分期，分型和治疗概述</h1><ul>
<li>肺癌是起源于支气管黏膜，腺体或肺泡上皮的肺部恶性肿瘤<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2014.12.45.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></li>
<li>肺癌的组织学分类：NSCLC约占所有肺癌的85%<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2014.19.04.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><ul>
<li>WHO基于肺癌的生物学特征、治疗和预后，将肺癌主要分为非小细胞肺癌NSCLC和小细胞肺癌SCLC</li>
<li>NSCLC包括除了SCLC以外的所有肺上皮癌，约占所有肺癌的85%，可以进一步细分为腺癌，鳞癌和大细胞癌三种主要类型</li>
</ul>
</li>
</ul>
<h2 id="腺癌比例持续升高，已经成为最常见的肺癌亚型"><a href="#腺癌比例持续升高，已经成为最常见的肺癌亚型" class="headerlink" title="腺癌比例持续升高，已经成为最常见的肺癌亚型"></a>腺癌比例持续升高，已经成为最常见的肺癌亚型</h2><ul>
<li>小细胞肺癌、鳞癌和大细胞肺癌的发病率在下降</li>
<li>腺癌在肺癌整体占比持续升高，成为男性和女性中最常见的肺癌亚型<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2014.22.38.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></li>
</ul>
<h2 id="NSCLC的临床分期"><a href="#NSCLC的临床分期" class="headerlink" title="NSCLC的临床分期"></a>NSCLC的临床分期</h2><p><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/v2-9401122ec74cf55f6e11941796e3f5e0_720w.jpg" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2014.36.40.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2014.36.55.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2014.26.31.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></p>
<h3 id="NSCLC患者的预后与分期密切相关"><a href="#NSCLC患者的预后与分期密切相关" class="headerlink" title="NSCLC患者的预后与分期密切相关"></a>NSCLC患者的预后与分期密切相关</h3><p><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2014.39.36.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></p>
<ul>
<li>超过一半的NSCLC患者在确诊时已经是晚期了（ⅢB-Ⅳ期）</li>
<li>NSCLC患者的生存期随分期升高显著下降，ⅢB-Ⅳ期患者的总体5年生存率&lt;5%</li>
</ul>
<h2 id="NSCLC的分子分型"><a href="#NSCLC的分子分型" class="headerlink" title="NSCLC的分子分型"></a>NSCLC的分子分型</h2><h3 id="肿瘤相关的关键信号通路"><a href="#肿瘤相关的关键信号通路" class="headerlink" title="肿瘤相关的关键信号通路"></a>肿瘤相关的关键信号通路</h3><ul>
<li>EGFR&#x2F;HER-2&#x2F;MET</li>
<li>RAS&#x2F;RAF&#x2F;MAPK</li>
<li>PI3K&#x2F;AKT&#x2F;mTOR</li>
<li>IGF &amp; ROS1</li>
<li>EML4-ALK，RET Fusion</li>
<li>p53，p16&#x2F;pRb<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2015.00.02.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><h3 id="基于驱动基因的分子分型"><a href="#基于驱动基因的分子分型" class="headerlink" title="基于驱动基因的分子分型"></a>基于驱动基因的分子分型</h3></li>
<li>对于NSCLC：考虑下述基因<br>* EGFR：表皮生长因子手提<br>* ALK：间变性淋巴瘤激酶<br>* ROS1：c-ros肉瘤致癌因子-受体酪氨酸激酶<br>* BRAF：v-Raf鼠肉瘤病毒癌基因同源物B</li>
<li>ⅢB-Ⅳ期NSCLC组织学诊断后，需要保留足够的组织，进行分子检测，根据分子分型指导治疗</li>
<li>非鳞NSCLC，无论临床特征，常规进行EGFR&#x2F;ALK&#x2F;ROS1&#x2F;BRAF分子检测</li>
<li>鳞状NSCLC，考虑进行EGFR&#x2F;ALK&#x2F;ROS1&#x2F;BRAF分子检测</li>
</ul>
<h3 id="我国NSCLC患者携带驱动基因的情况"><a href="#我国NSCLC患者携带驱动基因的情况" class="headerlink" title="我国NSCLC患者携带驱动基因的情况"></a>我国NSCLC患者携带驱动基因的情况</h3><ol>
<li>EGFR在EGFR在总体NSCLC患者中的突变率为28.2%；腺癌和鳞癌中，突变率分别为48.4%和4.3%</li>
<li>ALK在总体NSCLC患者中的突变率为5.6%；腺癌和鳞癌中，突变率分别为6.4%和2.0%</li>
<li>ROS1融合和BRAF突变在腺癌中更常见，突变率分别为3.14%和1.6%</li>
</ol>
<h2 id="NSCLC的诊断方法"><a href="#NSCLC的诊断方法" class="headerlink" title="NSCLC的诊断方法"></a>NSCLC的诊断方法</h2><h3 id="影像学"><a href="#影像学" class="headerlink" title="影像学"></a>影像学</h3><ol>
<li>用于诊断：胸部CT</li>
<li>用于影像分期：<ol>
<li>胸部增强CT</li>
<li>头部增强MR或增强CT</li>
<li>上腹部增强CT或B超</li>
<li>全身骨扫描</li>
</ol>
</li>
</ol>
<h3 id="获取标本"><a href="#获取标本" class="headerlink" title="获取标本"></a>获取标本</h3><ol>
<li>纤维支气管镜</li>
<li>经皮穿刺</li>
<li>淋巴结或浅表肿物活检</li>
<li>体腔积液细胞学检查</li>
</ol>
<h3 id="病理学"><a href="#病理学" class="headerlink" title="病理学"></a>病理学</h3><ol>
<li>形态学：常规HE染色</li>
<li>免疫组化染色</li>
<li>FISH</li>
</ol>
<h2 id="NSCLC可选的治疗手段"><a href="#NSCLC可选的治疗手段" class="headerlink" title="NSCLC可选的治疗手段"></a>NSCLC可选的治疗手段</h2><h3 id="手术"><a href="#手术" class="headerlink" title="手术"></a>手术</h3><ul>
<li>通常为早期患者的根治性治疗手段</li>
<li>可选的手术方案<ul>
<li>全肺切除</li>
<li>肺叶切除</li>
<li>肺段切除</li>
<li>袖状切除</li>
<li>电视辅助胸腔镜手术VATS</li>
</ul>
</li>
</ul>
<h3 id="放疗"><a href="#放疗" class="headerlink" title="放疗"></a>放疗</h3><ul>
<li>可用于所有分期的NSCLC</li>
</ul>
<h3 id="全身治疗"><a href="#全身治疗" class="headerlink" title="全身治疗"></a>全身治疗</h3><ul>
<li>化疗</li>
<li>靶向治疗</li>
<li>免疫治疗</li>
</ul>
<h1 id="药物在肺癌治疗中的角色"><a href="#药物在肺癌治疗中的角色" class="headerlink" title="药物在肺癌治疗中的角色"></a>药物在肺癌治疗中的角色</h1><h2 id="NSCLC治疗原则"><a href="#NSCLC治疗原则" class="headerlink" title="NSCLC治疗原则"></a>NSCLC治疗原则</h2><ul>
<li>Ⅰ ～ Ⅱ期采用以手术为主的综合治疗</li>
<li>可切除的Ⅲa期倾向于先辅助治疗（化疗为主）后手术切除</li>
<li>Ⅲb期（无恶性胸腔积液）及不可切除的Ⅲa期采取综合治疗（化疗&#x2F;放疗）</li>
<li>Ⅳ期及Ⅲb期（恶性胸腔积液）以化疗为主</li>
</ul>
<h2 id="SCLC的治疗原则"><a href="#SCLC的治疗原则" class="headerlink" title="SCLC的治疗原则"></a>SCLC的治疗原则</h2><ul>
<li>化疗为主，辅以手术和&#x2F;或放疗</li>
</ul>
<h1 id="常见的肺癌药物类别和代表药物"><a href="#常见的肺癌药物类别和代表药物" class="headerlink" title="常见的肺癌药物类别和代表药物"></a>常见的肺癌药物类别和代表药物</h1><h2 id="肺癌药物的发展"><a href="#肺癌药物的发展" class="headerlink" title="肺癌药物的发展"></a>肺癌药物的发展</h2><p><strong>1.0化疗时代：改变无药可用的局面</strong><br><strong>2.0靶向时代：精准治疗，获益提高</strong><br><strong>3.0免疫时代：提升五年生存率，带来持久的生存希望</strong><br>注：1.0 2.0 3.0时代仅表示肺癌治疗热点随着时间的更替，不代表方案的优劣</p>
<h2 id="常见化疗药物的类型"><a href="#常见化疗药物的类型" class="headerlink" title="常见化疗药物的类型"></a>常见化疗药物的类型</h2><ul>
<li>化疗药物主要通过干扰细胞分裂杀伤肿瘤细胞<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2019.46.55.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2019.48.35.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><ul>
<li>培美曲塞是一种多靶点的抗叶酸药物，具有其独特的优势<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2019.52.30.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><ul>
<li>不仅对耐药细胞提供了更加广泛的有效性，而且还能减缓或阻止其发展</li>
<li>同时抑制多个靶点，实际上是一种联合治疗<ul>
<li>具有有效药物联合治疗（多个靶点）的所有常规优势</li>
<li>没有严重缺点（联合治疗中每种药物的毒性总和）</li>
</ul>
</li>
<li>培美曲塞对非鳞NSCLC的效果非常好<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2019.55.31.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2019.56.38.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="常用的靶向药物类型"><a href="#常用的靶向药物类型" class="headerlink" title="常用的靶向药物类型"></a>常用的靶向药物类型</h2><ul>
<li>目前的NSCLC靶向治疗包括：EGFR抑制剂、ALK抑制剂和血管生成抑制剂</li>
<li>在应用EGFR和ALK靶向治疗前，需要先进行基因检测，明确突变的状态，阳性突变的患者才可以接受靶向治疗（有靶子才打）</li>
</ul>
<h3 id="EGFR抑制剂"><a href="#EGFR抑制剂" class="headerlink" title="EGFR抑制剂"></a>EGFR抑制剂</h3><ol>
<li>小分子TKI药物<ol>
<li>第一代：吉非替尼，厄洛替尼，埃可替尼</li>
<li>第二代：阿法替尼</li>
<li>第三代：奥西替尼</li>
</ol>
</li>
<li>EGFR单克隆抗体<ol>
<li>西洛昔单抗</li>
<li>耐妥昔单抗</li>
</ol>
</li>
</ol>
<ul>
<li>靶向治疗将晚期肺癌患者的总生存期提高到了2年以上<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2020.11.50.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></li>
</ul>
<h3 id="ALK抑制剂"><a href="#ALK抑制剂" class="headerlink" title="ALK抑制剂"></a>ALK抑制剂</h3><ol>
<li>第一代：克唑替尼</li>
<li>第二代：色瑞替尼、艾乐替尼</li>
<li>第三代：劳拉替尼</li>
</ol>
<h3 id="血管生成抑制剂"><a href="#血管生成抑制剂" class="headerlink" title="血管生成抑制剂"></a>血管生成抑制剂</h3><ol>
<li>代表性药物：贝伐珠单抗</li>
</ol>
<ul>
<li>肿瘤细胞需要血液供应来获得生长、存活和转移所需要的营养物质</li>
<li>血管生成抑制剂通过阻断肿瘤中的新血管生成，抑制肿瘤的生长</li>
</ul>
<h2 id="常用的免疫药物类型"><a href="#常用的免疫药物类型" class="headerlink" title="常用的免疫药物类型"></a>常用的免疫药物类型</h2><ul>
<li>免疫治疗的原理：T细胞介导的细胞免疫是抗肿瘤免疫的主要免疫反应</li>
<li>PD-1单抗或PD-L1单抗，分别与T细胞表面的PD-1或肿瘤细胞表面的PD-L1结合，阻断PD-1与PD-L1的相互作用，使T细胞恢复肿瘤杀伤功能<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2020.19.15.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></li>
</ul>
<ol>
<li>代表性药物：帕博利珠单抗，全球获批适应症数量最多，覆盖肿瘤种类最多的免疫治疗药物<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2020.21.36.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></li>
</ol>
<h1 id="常用的肺癌药物治疗方案和使用原则"><a href="#常用的肺癌药物治疗方案和使用原则" class="headerlink" title="常用的肺癌药物治疗方案和使用原则"></a>常用的肺癌药物治疗方案和使用原则</h1><h2 id="化疗使用原则"><a href="#化疗使用原则" class="headerlink" title="化疗使用原则"></a>化疗使用原则</h2><ol>
<li>KPS评分&lt;60或ECOG评分&gt;2的肺癌患者不宜进行化疗，SCLC患者可适当放宽<br>   <img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2020.26.35.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><br> KPS评分↑<br>  <img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2020.27.21.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'><br> ECOG评分↑</li>
<li>白细胞&lt;3✖️10^9 ，中性粒细胞&lt;1.5✖️10^9 ，血小板&lt;100✖️10^9 ，红细胞&lt;2✖️10^12，血红蛋白&lt;80g&#x2F;L的肺癌患者，原则上不宜化疗</li>
<li>严重的肝、肾功能异常，和&#x2F;或实验室指标严重异常，和&#x2F;或有严重并发症和感染、发热、出血倾向者，原则上不宜化疗</li>
<li>在化疗中如果出现了以下情况，需要考虑停药或者更换方案<ol>
<li>治疗2个周期后病变进展，或者在化疗周期的休息期中再度恶化的，应当停止原来的方案，酌情选用其他的方案</li>
<li>化疗不良反应达到3-4级，对患者生命有了明显的威胁，应当停药，下次治疗时调整治疗方案</li>
<li>出现严重的并发症，应当停药，下次治疗时调整治疗方案</li>
</ol>
</li>
<li>必须强调治疗方案的规范化和个体化<ol>
<li>必须掌握化疗的基本要求</li>
<li>除了常规应用止吐药物外，除了卡铂以外的铂类药物需要水化和利尿</li>
<li>化疗后要密切监测血常规和生化指标</li>
</ol>
</li>
<li>化疗后的疗效评价参考RECIST疗效评价标准</li>
</ol>
<h2 id="SCLC的常用药物治疗方案"><a href="#SCLC的常用药物治疗方案" class="headerlink" title="SCLC的常用药物治疗方案"></a>SCLC的常用药物治疗方案</h2><h3 id="一线治疗方案"><a href="#一线治疗方案" class="headerlink" title="一线治疗方案"></a>一线治疗方案</h3><ol>
<li>T1-2N0局限期小细胞肺癌推荐：肺叶切除术+肺门、纵隔淋巴结清扫+术后辅助化疗</li>
<li>超过T1-2N0局限期小细胞肺癌推荐：放、化疗为主的综合治疗<ul>
<li>化疗方案：依托泊苷联合顺铂或卡铂，写作EP方案或EC方案</li>
</ul>
</li>
<li>广泛期肺小细胞肺癌推荐化疗或在化疗（EP&#x2F;EC方案）基础上联合免疫治疗，如PD-L1单抗等为主的综合治疗</li>
<li>有局部症状，或伴随脑转移者，推荐在化疗基础上联合放疗，或其他局部治疗方法。<ul>
<li>化疗方案：EP、EC，伊利替康联合顺铂（IP）、伊利替康联合卡铂（IC）或者依托泊苷联合洛铂的方案（EL）</li>
<li>伊利替康的作用原理和依托泊苷一样，都是拓扑异构酶抑制剂</li>
</ul>
</li>
</ol>
<h3 id="二线治疗方案"><a href="#二线治疗方案" class="headerlink" title="二线治疗方案"></a>二线治疗方案</h3><ol>
<li>一线化疗6个月内复发或者进展的<ol>
<li>托普替康</li>
<li>伊利替康</li>
<li>吉西他滨（核苷酸类似物，抗代谢药）</li>
<li>长春瑞滨</li>
<li>替莫唑胺（烷化剂）</li>
<li>紫杉醇</li>
</ol>
</li>
<li>6个月后复发或进展的：初始治疗方案</li>
<li>鼓励患者参加新药临床试验</li>
</ol>
<h3 id="三线治疗方案"><a href="#三线治疗方案" class="headerlink" title="三线治疗方案"></a>三线治疗方案</h3><ol>
<li>安罗替尼</li>
<li>临床试验</li>
</ol>
<h2 id="NSCLC-围术期常用的药物方案"><a href="#NSCLC-围术期常用的药物方案" class="headerlink" title="NSCLC 围术期常用的药物方案"></a>NSCLC 围术期常用的药物方案</h2><h3 id="术后辅助化疗"><a href="#术后辅助化疗" class="headerlink" title="术后辅助化疗"></a>术后辅助化疗</h3><ol>
<li>完全切除的Ⅱ- Ⅲ期NSCLC，推荐含铂的双药方案，术后辅助化疗4个周期</li>
<li>辅助化疗起始于患者术后，体力状况基本恢复正常，一般在术后4-6周开始，最晚建议不超过手术后的3个月</li>
</ol>
<h3 id="新辅助化疗"><a href="#新辅助化疗" class="headerlink" title="新辅助化疗"></a>新辅助化疗</h3><ol>
<li>对可切除的Ⅲ期NSCLC，可以选择含铂的双药，2-3个周期的术前新辅助化疗</li>
<li>应及时评估疗效，监测并处理不良反应，避免增加手术后的并发症</li>
<li>手术一般在化疗结束后的2-4周进行</li>
<li>术后辅助化疗应当根据术前分期和新辅助化疗的疗效，有效者延续原来的方案，或者根据患者的耐受性酌情调整，无效者应当调整治疗方案</li>
<li>建议围手术前总共进行4个周期的化疗</li>
</ol>
<h3 id="围术期免疫治疗"><a href="#围术期免疫治疗" class="headerlink" title="围术期免疫治疗"></a>围术期免疫治疗</h3><ol>
<li>鼓励患者参与围手术期免疫治疗的临床试验</li>
<li>含铂化疗联合PD-1单抗新辅助治疗，或者术后PD-L1单抗辅助治疗，可以改善患者的病理学完全缓解率，或者延长无复发生存期</li>
</ol>
<h2 id="不能手术切除的NSCLC常用药物治疗方案"><a href="#不能手术切除的NSCLC常用药物治疗方案" class="headerlink" title="不能手术切除的NSCLC常用药物治疗方案"></a>不能手术切除的NSCLC常用药物治疗方案</h2><ol>
<li>推荐放疗、化疗联合，根据具体情况可选择同步或序贯放化疗。</li>
<li>同步治疗推荐化疗药物为依托泊苷联合顺铂（EP）或卡铂（EC）、培美曲塞联合顺铂或卡铂（仅限于非鳞NSCLC）、紫杉醇或多西他赛联合铂类</li>
<li>序贯治疗化疗药物为顺铂＋依托泊苷，顺铂＋紫杉醇，顺铂+多西他赛，顺铂或卡铂＋培美曲塞（非鳞非小细胞肺癌）</li>
<li>多学科团队讨论评价诱导治疗后降期患者手术的可能性，如能做到完全性切除，可考虑手术治疗</li>
<li>若同步放化疗后未出现疾病进展且不可根治性切除的I期NSCLC患者可考虑序贯度伐利尤单抗（人源化的PD-L1单克隆抗体，商品名英非凡）治疗1年</li>
</ol>
<h2 id="NSCLC-驱动基因阴性-晚期一线常用药物治疗方案"><a href="#NSCLC-驱动基因阴性-晚期一线常用药物治疗方案" class="headerlink" title="NSCLC 驱动基因阴性 晚期一线常用药物治疗方案"></a>NSCLC 驱动基因阴性 晚期一线常用药物治疗方案</h2><ol>
<li>对驱动基因阴性的患者，含铂两药方案是标准的一线化疗方案</li>
<li>非鳞癌患者可以在化疗基础上联合抗血管治疗，如贝伐珠单抗或血管内皮抑制蛋白；建议可行卡瑞利珠单抗，帕博利珠单抗，替雷利珠单抗，信迪利单抗（抗PD-1药物）或阿替利珠单抗联合培美曲塞为基础的含铂两药化疗</li>
<li>对鳞癌建议帕博利珠单抗、替雷利珠单抗联合紫杉醇，或信迪利单抗等联合吉西他滨含铂两药化疗。若患者PD-L1阳性（TPS≥1%），可行帕博利珠单抗单药治疗，其中PD-L1高表达（TPS≥50%）的患者免疫治疗获益更加显著。患者PD-L1高表达（TC≥50%或IC≥10%），亦可接受阿替利珠单抗单药治疗<br><img src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E6%88%AA%E5%B1%8F2024-03-16%2021.56.01.png" loading="lazy" onerror='this.onerror=null;this.src="/img/404.jpg"'></li>
</ol>
<ul>
<li><a target="_blank" rel="noopener" href="https://zhuanlan.zhihu.com/p/447474292">关于TPS、CPS、IPS、TC、IC等指标的友情链接文章</a></li>
</ul>
<h2 id="NSCLC-驱动基因阳性-晚期一线常用药物治疗方案"><a href="#NSCLC-驱动基因阳性-晚期一线常用药物治疗方案" class="headerlink" title="NSCLC 驱动基因阳性 晚期一线常用药物治疗方案"></a>NSCLC 驱动基因阳性 晚期一线常用药物治疗方案</h2><ol>
<li>EGFR基因突变（包括19外显子缺失、21外显子L858R和L861Q、18外显子G719X以及20外显子S768I）阳性的患者，可选择表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗，包括吉非替尼、厄洛替尼、埃克替尼、达可替尼、阿法替尼或奥希替尼。一线给予吉非替尼或厄洛替尼治疗时还可考虑联合化疗，厄洛替尼亦可联合贝伐珠单抗</li>
<li>ALK融合基因阳性的患者可选择阿来替尼、塞瑞替尼或克唑替尼治疗</li>
<li>ROS1融合基因阳性的患者，可选择克唑替尼治疗</li>
<li>C-met14跳跃突变、不能耐受化疗者可以选择赛沃替尼</li>
</ol>
<h2 id="NSCLC晚期患者维持常用药物方案"><a href="#NSCLC晚期患者维持常用药物方案" class="headerlink" title="NSCLC晚期患者维持常用药物方案"></a>NSCLC晚期患者维持常用药物方案</h2><ol>
<li>对一线治疗后达到疾病控制（完全缓解、部分缓解或稳定）的患者，可选择维持治疗</li>
<li>目前维持治疗有循证医学证据支持的药物有培美曲塞（非鳞癌）、贝伐珠单抗（非鳞癌）。有循证医学证据支持的换药维持治疗的药物有培美曲塞（非鳞癌）</li>
<li>使用免疫检查点抑制剂时若未出现疾病进展及不可耐受的不良反应，建议使用周期为2年</li>
<li>对于EGFR基因敏感突变患者可以选择EGFR-TKI进行维持治疗</li>
</ol>
<h2 id="NSCLC-晚期二线常用药物治疗方案"><a href="#NSCLC-晚期二线常用药物治疗方案" class="headerlink" title="NSCLC 晚期二线常用药物治疗方案"></a>NSCLC 晚期二线常用药物治疗方案</h2><h3 id="驱动基因阴性的患者"><a href="#驱动基因阴性的患者" class="headerlink" title="驱动基因阴性的患者"></a>驱动基因阴性的患者</h3><ul>
<li>驱动基因阴性的患者，应优先考虑化疗药物包括多西他赛、培美曲塞等</li>
<li>对于无驱动基因且组织学类型为鳞癌的患者，可选择使用阿法替尼</li>
<li>对于含铂两药联合化疗&#x2F; 靶向治疗失败后的NSCLC患者可选择免疫检查点抑制剂治疗。</li>
</ul>
<h3 id="驱动基因阳性的患者"><a href="#驱动基因阳性的患者" class="headerlink" title="驱动基因阳性的患者"></a>驱动基因阳性的患者</h3><ul>
<li>驱动基因突变阳性的患者，如果一线和维持治疗时没有应用相应的分子靶向药物，<strong>二线治疗时应优先应用分子靶向药物</strong><ul>
<li>一线EGFR-TKI治疗后耐药并且EGFR T790M突变阳性的患者，二线治疗时应优先使用三代EGFR-TKI，如奥希替尼、阿美替尼或伏美替尼</li>
<li>对于ALK融合阳性，一线接受克唑替尼治疗后出现耐药的患者，二线治疗时可选择塞瑞替尼或阿来替尼</li>
<li>一线分子靶向治疗耐药后若为寡进展或中枢神经系统进展，可继续靶向治疗基础上联合局部治疗，如放疗或手术等。</li>
<li>对于一线接受EGFR-TKI或者ALK抑制剂治疗出现耐药，二线治疗亦可根据患者的美国东部肿瘤协作组（ECOG）行为状态评分（PS）选择含铂两药或者单药化疗方案；若非鳞癌，可在此基础上联合抗血管药物，如贝伐珠单抗</li>
</ul>
</li>
<li>鼓励对患者进行“二次活检”，如果有相应的基因突变，可以考虑进行对应的靶向治疗</li>
</ul>

</article>
    
    

</div>
<div class="trm-post-next-prev row">
    <div class="col-lg-12">
        <!-- title -->
        <h5 class="trm-title-with-divider">
            Other Articles
            <span data-number="02"></span>
        </h5>
    </div>
    
        <div class="col-lg-6">
    <div class="trm-older-publications-card trm-scroll-animation trm-active-el">
        <div class="trm-older-publication">
            
            <a class="trm-op-top trm-anima-link" href="/%E9%99%88%E5%B7%8D%E5%AD%A6%E5%9F%BA%E5%9B%A0/EGFR%E5%9F%BA%E5%9B%A0%E9%9D%B6%E5%90%91%E6%B2%BB%E7%96%97/">
                <span class="trm-op-cover">
                    <img alt="cover" class="no-fancybox" src="/img/%E9%99%88%E5%B7%8D%E5%AD%A6%E5%9F%BA%E5%9B%A0/cover.jpg">
                </span>
                <h6 class="trm-op-title">EGFR基因靶向治疗</h6>
            </a>
            <div class="trm-divider trm-mb-15 trm-mt-20"></div>
            <ul class="trm-card-data trm-label">
                <li>24/10/24</li>
                <li>13:07</li>
                <li>科研</li>
            </ul>
        </div>
    </div>
</div>
    
    
        <div class="col-lg-6">
    <div class="trm-older-publications-card trm-scroll-animation trm-active-el">
        <div class="trm-older-publication">
            
            <a class="trm-op-top trm-anima-link" href="/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/%E5%AD%A4%E7%AB%8B%E6%80%A7%E8%82%BA%E7%BB%93%E8%8A%82%E7%9A%84%E8%AF%84%E4%BC%B0%E5%92%8C%E5%A4%84%E7%90%86/">
                <span class="trm-op-cover">
                    <img alt="cover" class="no-fancybox" src="/img/%E4%B8%B4%E5%BA%8A%E6%80%9D%E7%BB%B4/cover2.jpg">
                </span>
                <h6 class="trm-op-title">孤立性肺结节的评估和处理</h6>
            </a>
            <div class="trm-divider trm-mb-15 trm-mt-20"></div>
            <ul class="trm-card-data trm-label">
                <li>24/10/24</li>
                <li>13:07</li>
                <li>医学</li>
            </ul>
        </div>
    </div>
</div>
    
</div>

    



                    <div class="trm-divider footer-divider"></div>

                    <!-- footer -->
                    <footer class="trm-scroll-animation">

    

    

    
        <div class="trm-footer-item">
            <span>
                Powered by <a href="https://hexo.io" target="_blank" rel="noopener">Hexo</a> v7.1.1
            </span>
            <span class="footer-separator" data-separator=" | "></span>
            <span> 
                Theme - 
                <a rel="noopener" href='https://github.com/MaLuns/hexo-theme-async' target='_blank'>Async</a>
                v2.1.13
            </span>
        </div>
      

    
        <div class="trm-footer-item blog-run-long"></div>
     

     
</footer>
                    <!-- footer end -->

                </div>
            </div>
        </div>
    </div>
</div>
            <!-- body end -->

            

    <div id="post-toc" class="trm-post-toc">
      <div class="trm-post-toc-header">
        Article table of contents
				<span id="post-toc-top">
					TOP
				</span>
      </div>
      <div class="trm-post-toc-content">
        <ol class="trm-toc"><li class="trm-toc-item trm-toc-level-1" title="NSCLC的分类，分期，分型和治疗概述"><a rel="nofollow" class="trm-toc-link" href="#NSCLC的分类，分期，分型和治疗概述"><span class="trm-toc-number">1.</span> <span class="trm-toc-text">NSCLC的分类，分期，分型和治疗概述</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-2" title="腺癌比例持续升高，已经成为最常见的肺癌亚型"><a rel="nofollow" class="trm-toc-link" href="#腺癌比例持续升高，已经成为最常见的肺癌亚型"><span class="trm-toc-number">1.1.</span> <span class="trm-toc-text">腺癌比例持续升高，已经成为最常见的肺癌亚型</span></a></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC的临床分期"><a rel="nofollow" class="trm-toc-link" href="#NSCLC的临床分期"><span class="trm-toc-number">1.2.</span> <span class="trm-toc-text">NSCLC的临床分期</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="NSCLC患者的预后与分期密切相关"><a rel="nofollow" class="trm-toc-link" href="#NSCLC患者的预后与分期密切相关"><span class="trm-toc-number">1.2.1.</span> <span class="trm-toc-text">NSCLC患者的预后与分期密切相关</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC的分子分型"><a rel="nofollow" class="trm-toc-link" href="#NSCLC的分子分型"><span class="trm-toc-number">1.3.</span> <span class="trm-toc-text">NSCLC的分子分型</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="肿瘤相关的关键信号通路"><a rel="nofollow" class="trm-toc-link" href="#肿瘤相关的关键信号通路"><span class="trm-toc-number">1.3.1.</span> <span class="trm-toc-text">肿瘤相关的关键信号通路</span></a></li><li class="trm-toc-item trm-toc-level-3" title="基于驱动基因的分子分型"><a rel="nofollow" class="trm-toc-link" href="#基于驱动基因的分子分型"><span class="trm-toc-number">1.3.2.</span> <span class="trm-toc-text">基于驱动基因的分子分型</span></a></li><li class="trm-toc-item trm-toc-level-3" title="我国NSCLC患者携带驱动基因的情况"><a rel="nofollow" class="trm-toc-link" href="#我国NSCLC患者携带驱动基因的情况"><span class="trm-toc-number">1.3.3.</span> <span class="trm-toc-text">我国NSCLC患者携带驱动基因的情况</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC的诊断方法"><a rel="nofollow" class="trm-toc-link" href="#NSCLC的诊断方法"><span class="trm-toc-number">1.4.</span> <span class="trm-toc-text">NSCLC的诊断方法</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="影像学"><a rel="nofollow" class="trm-toc-link" href="#影像学"><span class="trm-toc-number">1.4.1.</span> <span class="trm-toc-text">影像学</span></a></li><li class="trm-toc-item trm-toc-level-3" title="获取标本"><a rel="nofollow" class="trm-toc-link" href="#获取标本"><span class="trm-toc-number">1.4.2.</span> <span class="trm-toc-text">获取标本</span></a></li><li class="trm-toc-item trm-toc-level-3" title="病理学"><a rel="nofollow" class="trm-toc-link" href="#病理学"><span class="trm-toc-number">1.4.3.</span> <span class="trm-toc-text">病理学</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC可选的治疗手段"><a rel="nofollow" class="trm-toc-link" href="#NSCLC可选的治疗手段"><span class="trm-toc-number">1.5.</span> <span class="trm-toc-text">NSCLC可选的治疗手段</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="手术"><a rel="nofollow" class="trm-toc-link" href="#手术"><span class="trm-toc-number">1.5.1.</span> <span class="trm-toc-text">手术</span></a></li><li class="trm-toc-item trm-toc-level-3" title="放疗"><a rel="nofollow" class="trm-toc-link" href="#放疗"><span class="trm-toc-number">1.5.2.</span> <span class="trm-toc-text">放疗</span></a></li><li class="trm-toc-item trm-toc-level-3" title="全身治疗"><a rel="nofollow" class="trm-toc-link" href="#全身治疗"><span class="trm-toc-number">1.5.3.</span> <span class="trm-toc-text">全身治疗</span></a></li></ol></li></ol></li><li class="trm-toc-item trm-toc-level-1" title="药物在肺癌治疗中的角色"><a rel="nofollow" class="trm-toc-link" href="#药物在肺癌治疗中的角色"><span class="trm-toc-number">2.</span> <span class="trm-toc-text">药物在肺癌治疗中的角色</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-2" title="NSCLC治疗原则"><a rel="nofollow" class="trm-toc-link" href="#NSCLC治疗原则"><span class="trm-toc-number">2.1.</span> <span class="trm-toc-text">NSCLC治疗原则</span></a></li><li class="trm-toc-item trm-toc-level-2" title="SCLC的治疗原则"><a rel="nofollow" class="trm-toc-link" href="#SCLC的治疗原则"><span class="trm-toc-number">2.2.</span> <span class="trm-toc-text">SCLC的治疗原则</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-1" title="常见的肺癌药物类别和代表药物"><a rel="nofollow" class="trm-toc-link" href="#常见的肺癌药物类别和代表药物"><span class="trm-toc-number">3.</span> <span class="trm-toc-text">常见的肺癌药物类别和代表药物</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-2" title="肺癌药物的发展"><a rel="nofollow" class="trm-toc-link" href="#肺癌药物的发展"><span class="trm-toc-number">3.1.</span> <span class="trm-toc-text">肺癌药物的发展</span></a></li><li class="trm-toc-item trm-toc-level-2" title="常见化疗药物的类型"><a rel="nofollow" class="trm-toc-link" href="#常见化疗药物的类型"><span class="trm-toc-number">3.2.</span> <span class="trm-toc-text">常见化疗药物的类型</span></a></li><li class="trm-toc-item trm-toc-level-2" title="常用的靶向药物类型"><a rel="nofollow" class="trm-toc-link" href="#常用的靶向药物类型"><span class="trm-toc-number">3.3.</span> <span class="trm-toc-text">常用的靶向药物类型</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="EGFR抑制剂"><a rel="nofollow" class="trm-toc-link" href="#EGFR抑制剂"><span class="trm-toc-number">3.3.1.</span> <span class="trm-toc-text">EGFR抑制剂</span></a></li><li class="trm-toc-item trm-toc-level-3" title="ALK抑制剂"><a rel="nofollow" class="trm-toc-link" href="#ALK抑制剂"><span class="trm-toc-number">3.3.2.</span> <span class="trm-toc-text">ALK抑制剂</span></a></li><li class="trm-toc-item trm-toc-level-3" title="血管生成抑制剂"><a rel="nofollow" class="trm-toc-link" href="#血管生成抑制剂"><span class="trm-toc-number">3.3.3.</span> <span class="trm-toc-text">血管生成抑制剂</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-2" title="常用的免疫药物类型"><a rel="nofollow" class="trm-toc-link" href="#常用的免疫药物类型"><span class="trm-toc-number">3.4.</span> <span class="trm-toc-text">常用的免疫药物类型</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-1" title="常用的肺癌药物治疗方案和使用原则"><a rel="nofollow" class="trm-toc-link" href="#常用的肺癌药物治疗方案和使用原则"><span class="trm-toc-number">4.</span> <span class="trm-toc-text">常用的肺癌药物治疗方案和使用原则</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-2" title="化疗使用原则"><a rel="nofollow" class="trm-toc-link" href="#化疗使用原则"><span class="trm-toc-number">4.1.</span> <span class="trm-toc-text">化疗使用原则</span></a></li><li class="trm-toc-item trm-toc-level-2" title="SCLC的常用药物治疗方案"><a rel="nofollow" class="trm-toc-link" href="#SCLC的常用药物治疗方案"><span class="trm-toc-number">4.2.</span> <span class="trm-toc-text">SCLC的常用药物治疗方案</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="一线治疗方案"><a rel="nofollow" class="trm-toc-link" href="#一线治疗方案"><span class="trm-toc-number">4.2.1.</span> <span class="trm-toc-text">一线治疗方案</span></a></li><li class="trm-toc-item trm-toc-level-3" title="二线治疗方案"><a rel="nofollow" class="trm-toc-link" href="#二线治疗方案"><span class="trm-toc-number">4.2.2.</span> <span class="trm-toc-text">二线治疗方案</span></a></li><li class="trm-toc-item trm-toc-level-3" title="三线治疗方案"><a rel="nofollow" class="trm-toc-link" href="#三线治疗方案"><span class="trm-toc-number">4.2.3.</span> <span class="trm-toc-text">三线治疗方案</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC 围术期常用的药物方案"><a rel="nofollow" class="trm-toc-link" href="#NSCLC-围术期常用的药物方案"><span class="trm-toc-number">4.3.</span> <span class="trm-toc-text">NSCLC 围术期常用的药物方案</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="术后辅助化疗"><a rel="nofollow" class="trm-toc-link" href="#术后辅助化疗"><span class="trm-toc-number">4.3.1.</span> <span class="trm-toc-text">术后辅助化疗</span></a></li><li class="trm-toc-item trm-toc-level-3" title="新辅助化疗"><a rel="nofollow" class="trm-toc-link" href="#新辅助化疗"><span class="trm-toc-number">4.3.2.</span> <span class="trm-toc-text">新辅助化疗</span></a></li><li class="trm-toc-item trm-toc-level-3" title="围术期免疫治疗"><a rel="nofollow" class="trm-toc-link" href="#围术期免疫治疗"><span class="trm-toc-number">4.3.3.</span> <span class="trm-toc-text">围术期免疫治疗</span></a></li></ol></li><li class="trm-toc-item trm-toc-level-2" title="不能手术切除的NSCLC常用药物治疗方案"><a rel="nofollow" class="trm-toc-link" href="#不能手术切除的NSCLC常用药物治疗方案"><span class="trm-toc-number">4.4.</span> <span class="trm-toc-text">不能手术切除的NSCLC常用药物治疗方案</span></a></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC 驱动基因阴性 晚期一线常用药物治疗方案"><a rel="nofollow" class="trm-toc-link" href="#NSCLC-驱动基因阴性-晚期一线常用药物治疗方案"><span class="trm-toc-number">4.5.</span> <span class="trm-toc-text">NSCLC 驱动基因阴性 晚期一线常用药物治疗方案</span></a></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC 驱动基因阳性 晚期一线常用药物治疗方案"><a rel="nofollow" class="trm-toc-link" href="#NSCLC-驱动基因阳性-晚期一线常用药物治疗方案"><span class="trm-toc-number">4.6.</span> <span class="trm-toc-text">NSCLC 驱动基因阳性 晚期一线常用药物治疗方案</span></a></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC晚期患者维持常用药物方案"><a rel="nofollow" class="trm-toc-link" href="#NSCLC晚期患者维持常用药物方案"><span class="trm-toc-number">4.7.</span> <span class="trm-toc-text">NSCLC晚期患者维持常用药物方案</span></a></li><li class="trm-toc-item trm-toc-level-2" title="NSCLC 晚期二线常用药物治疗方案"><a rel="nofollow" class="trm-toc-link" href="#NSCLC-晚期二线常用药物治疗方案"><span class="trm-toc-number">4.8.</span> <span class="trm-toc-text">NSCLC 晚期二线常用药物治疗方案</span></a><ol class="trm-toc-child"><li class="trm-toc-item trm-toc-level-3" title="驱动基因阴性的患者"><a rel="nofollow" class="trm-toc-link" href="#驱动基因阴性的患者"><span class="trm-toc-number">4.8.1.</span> <span class="trm-toc-text">驱动基因阴性的患者</span></a></li><li class="trm-toc-item trm-toc-level-3" title="驱动基因阳性的患者"><a rel="nofollow" class="trm-toc-link" href="#驱动基因阳性的患者"><span class="trm-toc-number">4.8.2.</span> <span class="trm-toc-text">驱动基因阳性的患者</span></a></li></ol></li></ol></li></ol>
      </div>
    </div>

            
<div class="trm-fixed-container">
    
        <div class="trm-fixed-btn post-toc-btn" data-title="Open toc">
            <i class="iconfont fas fa-th-list"></i>
        </div>
    
    
        <div class="trm-fixed-btn" data-title="Read Mode" onclick="asyncFun.switchReadMode()">
            <i class="iconfont fas fa-book-reader"></i>
        </div>
    
    
        <div class="trm-fixed-btn hidden-md" data-title="Toggle between single-column and double-column" onclick="asyncFun.switchSingleColumn()">
            <i class="iconfont fas fa-arrows-alt-h"></i>
        </div>
    
    <div id="trm-back-top" class="trm-fixed-btn" data-title="Back To Top">
        <i class="iconfont fas fa-arrow-up"></i>
    </div>
</div>
        </div>
      </div>
      <!-- scroll container end -->
  </div>
  <!-- app wrapper end -->

  
    <div class="trm-search-popup">
        <div class="trm-search-wrapper">
            <div class="form trm-search-form">
                <div class="trm-search-input-icon">
                    <i class="iconfont fas fa-search"></i>
                </div>
                <input class="trm-search-input" type="text" placeholder="Searching...">
                <div class="trm-search-btn-close">
                    <i class="iconfont fas fa-times"></i>
                </div>
            </div>
            <div class="trm-search-result-container">
                <div class="trm-search-empty">
                    Find Something Special?
                </div>
            </div>
            <div class="trm-search-footer">
                <div class="trm-search-stats"></div>
                <ul class="trm-search-commands">
                    <li>
                        <kbd class="command-palette-commands-key">
                            <svg width="15" height="15" aria-label="Escape key" role="img">
                                <g fill="none" stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"
                                    stroke-width="1.2">
                                    <path
                                        d="M13.6167 8.936c-.1065.3583-.6883.962-1.4875.962-.7993 0-1.653-.9165-1.653-2.1258v-.5678c0-1.2548.7896-2.1016 1.653-2.1016.8634 0 1.3601.4778 1.4875 1.0724M9 6c-.1352-.4735-.7506-.9219-1.46-.8972-.7092.0246-1.344.57-1.344 1.2166s.4198.8812 1.3445.9805C8.465 7.3992 8.968 7.9337 9 8.5c.032.5663-.454 1.398-1.4595 1.398C6.6593 9.898 6 9 5.963 8.4851m-1.4748.5368c-.2635.5941-.8099.876-1.5443.876s-1.7073-.6248-1.7073-2.204v-.4603c0-1.0416.721-2.131 1.7073-2.131.9864 0 1.6425 1.031 1.5443 2.2492h-2.956">
                                    </path>
                                </g>
                            </svg>
                        </kbd>
                        <span class="command-palette-Label">to close</span>
                    </li>
                </ul>
            </div>
        </div>
    </div>

  <!-- Plugin -->




    
    
<script src="https://unpkg.com/@fancyapps/ui@4.0/dist/fancybox.umd.js"></script>

    

    

    
        
<script src="https://unpkg.com/hexo-generator-searchdb@1.4.0/dist/search.js"></script>

        <script src="/js/plugins/local_search.js?v=2.1.13"></script>
    

    <!-- 数学公式 -->
    

    <!-- 评论插件 -->
    
        

        
    

		




    <!-- Service Worker -->
    
    <script>
        "serviceWorker" in navigator ?
        navigator.serviceWorker.register('/sw.js').then(function () {
            navigator.serviceWorker.controller ? 
             console.log("Assets cached by the controlling service worker.") :
             console.log("Please reload this page to allow the service worker to handle network operations.")
        }).catch(function (e) {
            console.log("ERROR: " + e)
        }) : console.log("Service workers are not supported in the current browser.")
    </script>

    <!-- baidu push -->
    


<script id="async-script" src="/js/main.js?v=2.1.13"></script>

<!-- CDN -->


    

    

    



</body>

</html>